Build us an e-commerce website

We are launching our e-commerce site for the US market. We have two formulated products that will be sold separately and as a bundle. The site layout and all the content ready to by uploaded in Word Press format. We need a developer who knows the life sciences/pharmaceutical space and who is creative with a scientific/medical feel. Our corporate website, [login to view URL] is quite informative. see Profile below: CanaQuest Medical, an award-winning, life-sciences company, is focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company intends to treat neurological conditions, such as anxiety, depression, schizophrenia, and Post Traumatic Stress Disorder “PTSD”, including addiction. CanaQuest’s mission is to advance botanical-based medicine to the forefront by deploying best-practice science & medicine, clinical research, and emerging technologies. The Company is the industry partner for research and product development with Dr. Steven Laviolette, a professor and neuroscientist, at Western University, London, Ontario Canada. Dr. Laviolette is a scientific veteran with 20 years of research experience in the field of mental health and cannabinoids and he oversees a dedicated team of 13 scientists. [login to view URL] Dr. Laviolette has made an amazing discovery: Mentanine® Formulation (plant-based cannabidiol “CBD” and natural IP formula) Double acting formula – acting on the central nervous system (the brain) and endocannabinoid system New Pathway Discovery: The formulated ingredients bond and synergistically attach to the PPAR receptor allowing the Mentanine® formula to cross the blood-brain barrier “BBB” to target the central nervous system (the brain) with amplified effects and efficacy. CBD by itself does not do this. With improved efficacy, Mentanine® addresses neurological conditions such as anxiety, depression, PTSD, and addiction. Dr. Laviolette stated, “Our CBD-based formulation works synergistically and has multiple times the efficacy compared to other approved CBD products on the market. This discovery sets the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects. There is strong evidence that this formulation is also a very promising anti-epilepsy treatment, which I believe makes the formulation even more promising for these applications.” Mentanine® pre-clinical trial results: 1. Indicated 10 times + the efficacy as compared to CBD alone 2. Reduced Anxiety, Depression, PTSD and Addictive effects 3. Showed significant reduction of inflammation, which could be beneficial for pain management. Pre-clinical trial results - published in peer-reviewed European Journal of Neuroscience. Oct. 2020. Mentanine® can be administrated with a significantly faster rate of absorption and significantly smaller doses compared to other CBD medications, therefore, reducing or even eliminating the negative side effects of liver toxicity caused by high consumption of CBD oils available today. The Company will be selling Mentanine® to customers in the US under the 2018 US Farm Bill and Assembly Bill 45, California.